The recommended dose of palivizumab is 15 mg/kg of body weight, given once a month during anticipated periods of RSV risk in the community. The first dose should be administered prior to commencement of the RSV season and subsequent doses should be administered monthly throughout the RSV season. In the northern hemisphere, the RSV season typically commences in November and lasts through April, but RSV activity may begin earlier or persist later in a community. To avoid risk of reinfection, it is recommended that children receiving palivizumab who become infected with RSV continue to receive monthly doses of palivizumab for the duration of the RSV season.
Palivizumab is administered in a dose of 15 mg/kg once a month intramuscularly, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve. The injection should be given using standard aseptic technique. The dose per month = patient weight (kg) x 15 mg/kg ÷ 100 mg/ml of palivizumab. Injection volumes over 1 mL should be given as a divided dose.
The efficacy of Synagis at doses less than 15 mg per kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.
Palivizumab is to be administered by intramuscular injection only.
To prevent the transmission of infectious diseases, sterile disposable syringes and needles should be used. Do not reuse syringes and needles.
Preparation for Administration: Liquid Formulation (100 mg/mL in 0.5 mL or 1 mL vials): Liquid palivizumab should not be mixed with any medications or diluents.
Administration Instructions (Liquid Formulation): Both the 0.5 mL and 1 mL vials contain an overfill to allow the withdrawal of 50 mg or 100 mg, respectively.
DO NOT DILUTE THE PRODUCT.
DO NOT SHAKE VIAL.
To administer, remove the tab portion of the vial cap and clean the stopper with 70% ethanol or equivalent. Insert the needle into the vial and withdraw an appropriate volume of solution into the syringe.
Palivizumab does not contain a preservative and should be administered immediately after drawing the dose into the syringe.
Single-use vial. Do not re-enter the vial after withdrawal of drug. Discard unused contents.